As of Jul 02
| -0.14 / -4.15%|
The 1 analysts offering 12-month price forecasts for Rosetta Genomics Ltd have a median target of 5.00, with a high estimate of 5.00 and a low estimate of 5.00. The median estimate represents a +54.80% increase from the last price of 3.23.
The current consensus among 1 polled investment analysts is to Buy stock in Rosetta Genomics Ltd. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.